Probiotic Blend for Celiac Disease
Launched by UNIVERSIDADE DO EXTREMO SUL CATARINENSE - UNIDADE ACADEMICA DE CIECIAS DA SAUDE · Dec 2, 2022
Trial Information
Current as of January 17, 2025
Unknown status
Keywords
ClinConnect Summary
This clinical trial is studying a special combination of probiotics (which are helpful bacteria) to see if it can reduce symptoms and improve the quality of life for people with celiac disease. Celiac disease is an autoimmune condition where eating gluten (a protein found in wheat, barley, and rye) can damage the intestines. The trial will involve 118 adult volunteers, aged 18 to 65, who have been diagnosed with celiac disease. Participants will be split into two groups: one will receive the probiotic blend, and the other will receive a placebo (a non-active substance). The study will last for 90 days and will include three visits where participants will fill out questionnaires about their symptoms and overall well-being.
To participate in this trial, individuals must provide written consent and be diagnosed with celiac disease by a doctor. However, those who have recently taken probiotics or have certain health conditions, like uncontrolled bowel diseases or heart problems, will not be eligible. This study is an opportunity for patients to potentially find relief from their symptoms while helping researchers learn more about the benefits of probiotics for celiac disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of Free and Informed Consent in writing, signed and dated;
- • Age according to the indicated population;
- • Patients diagnosed with celiac disease by a specialist physician.
- Exclusion Criteria:
- • History of daily consumption of probiotics, fermented milk and or yogurt;
- • subjects known to have demonstrated a prior reaction, including anaphylaxis, to any substance in the composition of the study product;
- • Subjects who have uncompensated blood pressure;
- • history of heart disease, including valvular heart disease or any implantable device;
- • subjects with active, uncontrolled bowel disease such as Crohn's disease or ulcerative colitis;
- • another clinical trial.
About Universidade Do Extremo Sul Catarinense Unidade Academica De Ciecias Da Saude
The Universidade do Extremo Sul Catarinense - Unidade Acadêmica de Ciências da Saúde is a leading academic institution dedicated to advancing health sciences through innovative research and education. Located in Brazil, this university is committed to fostering a collaborative environment that promotes scientific inquiry and clinical research excellence. By engaging in clinical trials, the institution aims to contribute valuable insights into healthcare practices and improve patient outcomes, while also training the next generation of health professionals to address complex health challenges. Their focus on interdisciplinary approaches ensures a comprehensive understanding of health issues, making significant contributions to the scientific community and society at large.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Criciúma, Santa Catarina, Brazil
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials